Evaluation of Survival Outcomes Among Black and White Patients with Metastatic Castration-resistant Prostate Cancer: A Systematic Review and Meta-analysis

Yang, Jie; Xiong, Xingyu; Zheng, Weitao; Liao, Xinyang; Xu, Hang; Yang, Lu; Wei, Qiang

doi:10.1016/j.euros.2024.01.004

Cited by 1 publication

(3 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 23 Evidence has suggested that Black men with metastatic, castrate-resistant PCa have improved survival with systemic agent treatment compared with White men. 24 , 25 Despite this, Black men were less likely to receive treatment compared with White men when the PCa worsened, which is certain to play a part in the disparity of outcomes. 26 …”

Section: Discussionmentioning

confidence: 99%

“…This was further highlighted by a study reporting that Black men had significantly higher rates of PCa detection on prostate biopsy with similar PSA levels (49% compared with 39% for non-Hispanic White men at a PSA level of 4.0 ng/mL [to convert to micrograms per liter, multiply by 1]) . Evidence has suggested that Black men with metastatic, castrate-resistant PCa have improved survival with systemic agent treatment compared with White men . Despite this, Black men were less likely to receive treatment compared with White men when the PCa worsened, which is certain to play a part in the disparity of outcomes …”

Section: Discussionmentioning

confidence: 99%

“…Prostate Cancer Among Black Men in Canada castrate-resistant PCa have improved survival with systemic agent treatment compared with White men. 24,25 Despite this, Black men were less likely to receive treatment compared with White men when the PCa worsened, which is certain to play a part in the disparity of outcomes. 26 Important to note in this study is the age of PCa diagnosis of Black men is significantly younger than non-Black men.…”

Section: Jama Network Open | Urologymentioning

confidence: 99%

See 2 more Smart Citations

Prostate Cancer Among Black Men in Canada

Albers,

Bashir,

Mookerji

et al. 2024

JAMA Netw Open

View full text Add to dashboard Cite

ImportanceProstate cancer is a prevalent disease among men worldwide, exhibiting substantial heterogeneity in presentation and outcomes influenced by various factors, including race and ethnicity. Disparities in incidence, stage at diagnosis, and survival rates have been observed between Black men and those of other races and ethnicities.ObjectiveTo compare prostate cancer outcomes between Black men and men with other race (Asian, Hispanic, Indigenous, Middle Eastern, White, Multiracial, and Other) in a universal health care system, with race and ethnicity self-reported.Design, Setting, and ParticipantsThis was a prospective, observational cohort study of men diagnosed with prostate cancer between June 1, 2014, and August 28, 2023, who self-identified race and ethnicity. Participants included men who had been prospectively enrolled in the Alberta Prostate Cancer Research Initiative from the 2 major urology referral centers in Alberta (University of Alberta and University of Calgary). All men with prostate cancer enrolled in the initiative were included.ExposureRace and ethnicity.Main Outcomes and MeasuresThe primary outcome was the stage and grade of prostate cancer at diagnosis. Further outcomes included age and prostate-specific antigen level at diagnosis, initial treatment modality, time from diagnosis to initial treatment, and prostate cancer–specific, metastasis-free, and overall survivals.ResultsA total of 6534 men were included; 177 (2.7%) were Black, and 6357 (97.3%) had another race or ethnicity. Men who identified as Black were diagnosed with prostate cancer at an earlier age (mean [SD], 62.0 [8.2] compared with 64.6 [7.7] years; P &lt; .001) and had a lower Charlson Comorbidity Index rating (14% compared with 7% ≤ 1; P &lt; .001) compared with men of other races. Men who identified as Black had similar prostate-specific antigen levels at diagnosis, TNM category (74% vs 74% with T1-T2; P = .83) and Gleason Grade Group (34% compared with 35% Gleason Grade Group 1; P = .63). Black men had similar rates of prostate cancer–specific (hazard ratio [HR], 1.10; 95% CI, 0.41-2.97; P = .85), metastasis-free (HR, 0.88; 95% CI, 0.42-1.46; P = .44), and overall (HR, 0.55; 95% CI, 0.25-1.24; P = .15) survival.Conclusions and RelevanceThe findings of this cohort study suggest that Black men, despite being diagnosed at a younger age, experience comparable prostate cancer outcomes compared with men of other races.

show abstract